NEW YORK, March 13, 2017 /PRNewswire/ --
Today, Stock-Callers.com unveils four Generic Drugs stocks for assessment:Galectin Therapeutics Inc. (NASDAQ: GALT), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Innocoll Holdings PLC (NASDAQ: INNL), and Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH). These companies belong to the Healthcare sector which put up moderate gains
Norcross, Georgia-based Galectin Therapeutics Inc.'s shares jumped 6.59%, finishing last Friday's session at $1.94. A total volume of 2.30 million shares was traded, which was above their three months average volume of 517,710 shares. Over the last month and the previous three months, the stock has advanced 65.81% and 122.99%, respectively. Furthermore, the Company's shares have surged 97.96% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 50.15% and 43.93%, respectively. Additionally, shares of Galectin Therapeutics, which engages in the research and development of therapies for fibrotic disease and cancer, have a Relative Strength Index (RSI) of 64.66.
On March 06th, 2017, Galectin Therapeutics announced results from an exploratory, Phase-2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis. Data to be presented at Maui Derm for Dermatologists on March 20th to March 23rd, 2017 in Maui, Hawaii, showed no serious adverse events and achieved an average PASI (Psoriasis Area and Severity Index) reduction of over 50% in all patients that participated in the 24-week trial. Your complete research report on GALT can be retrieved for free at: http://stock-callers.com/registration/?symbol=GALT
On Friday, shares in Coral Gables, Florida-based Catalyst Pharmaceuticals Inc. ended the session flat at $1.11. The stock recorded a trading volume of 124,116 shares. The Company's shares have gained 5.71% on an YTD basis. The stock is trading above its 200-day moving average by 10.22%. Moreover, shares of Catalyst Pharma, which focuses on the development and commercialization of therapies for people with rare debilitating diseases, have an RSI of 44.39.
On March 09th, 2017, Catalyst Pharmaceuticals announced that it will release Q4 and year-end 2016 financial results after market close on March 15th, 2017. Further, Catalyst Pharma's management will host an investment-community conference call at 8:30 a.m. ET on March 16th, 2017, to discuss the financial results and to provide a corporate update. A free report on CPRX is just a click away at: http://stock-callers.com/registration/?symbol=CPRX
Athlone, Ireland headquartered Innocoll Holdings PLC's stock surged 9.16%, to close the day at $0.80. A total volume of 1.04 million shares was traded, which was higher than their three months average volume of 517,680 shares. The Company's shares have advanced 37.40% in the last one month and 15.49% on an YTD basis. The stock is trading 9.24% above its 50-day moving average. Additionally, shares of Innocoll Holdings, which manufactures and sells collagen-based pharmaceutical products and devices in Europe, Middle East, Asia, and the US, have an RSI of 64.01. Sign up for your complimentary research report on INNL at: http://stock-callers.com/registration/?symbol=INNL
Shares in Watertown, Massachusetts headquartered Tetraphase Pharmaceuticals Inc. recorded a trading volume of 3.18 million shares, which was above their three months average volume of 394,520 shares. The stock ended at $6.95, up 14.31% from the last trading session. The Company's shares have surged 64.69% in the past month, 54.79% over the previous three months, and 72.46% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 48.23% and 66.43%, respectively. Furthermore, shares of Tetraphase Pharma, which develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections, have an RSI of 76.62.
On March 08th, 2017, Tetraphase reported a net loss of $22.5 million, or $0.61 per share for Q4 2016, compared to a net loss of $18.1 million, or $0.50 per share, for Q4 2015. The Company's revenues were $1.1 million compared to $2.5 million for Q4 2015. As of December 31st, 2016, Tetraphase had cash and cash equivalents of $142.1 million and 36.9 million shares outstanding. The Company expects that its cash and cash equivalents, as well as expected revenue from its US government awards, will be sufficient to fund operations into at least the second half of 2018.
On March 09th, 2017, research firm Stifel reiterated its 'Hold' rating on the Company's stock with an increase of the target price from $5 a share to $7 a share. Register for free on Stock-Callers.com and download the latest research report on TTPH at: http://stock-callers.com/registration/?symbol=TTPH
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!